-transparent.png){kind=logo}
Fifteen healthy castrated male dogs were separated into three treatment groups that were administered etodolac, aspirin and a placebo orally, respectively. All treatments were continued for 28 days. The animals were examined endoscopically on days 0, 3, 7, 10, 14, 17, 21, 24 and 28. There were no gastrointestinal mucosal lesions in either the etodolac or the placebo group, whereas some gastric lesions developed in the aspirin group after day 17. We considered that etodolac could be used for long-term treatments in dogs with fewer side-effects on the gastric mucosa than aspirin.
Related Publications
K Nishihara, and
H Kikuchi, and
T Kanno, and
S Tanabe, and
T Sarashina, and
Y Uzuka
January 1999,
Journal of veterinary internal medicine,
K Nishihara, and
H Kikuchi, and
T Kanno, and
S Tanabe, and
T Sarashina, and
Y Uzuka
May 1984,
Clinical pharmacology and therapeutics,
K Nishihara, and
H Kikuchi, and
T Kanno, and
S Tanabe, and
T Sarashina, and
Y Uzuka
January 1986,
Pharmacotherapy,
K Nishihara, and
H Kikuchi, and
T Kanno, and
S Tanabe, and
T Sarashina, and
Y Uzuka
March 1968,
Journal of the American Veterinary Medical Association,
K Nishihara, and
H Kikuchi, and
T Kanno, and
S Tanabe, and
T Sarashina, and
Y Uzuka
February 1973,
Toxicology and applied pharmacology,
K Nishihara, and
H Kikuchi, and
T Kanno, and
S Tanabe, and
T Sarashina, and
Y Uzuka
July 2003,
Alimentary pharmacology & therapeutics,
K Nishihara, and
H Kikuchi, and
T Kanno, and
S Tanabe, and
T Sarashina, and
Y Uzuka
April 1986,
The Journal of rheumatology,
K Nishihara, and
H Kikuchi, and
T Kanno, and
S Tanabe, and
T Sarashina, and
Y Uzuka
April 1987,
The Journal of rheumatology,
K Nishihara, and
H Kikuchi, and
T Kanno, and
S Tanabe, and
T Sarashina, and
Y Uzuka
June 2011,
Nature reviews. Gastroenterology & hepatology,
K Nishihara, and
H Kikuchi, and
T Kanno, and
S Tanabe, and
T Sarashina, and
Y Uzuka
January 2019,
Frontiers in veterinary science,
